Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 12/20 | 0.40 |
| ▸ | AURKA | O14965 | 8/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.38 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14536988 | 0.96 | AURKB (0.42) | CHEK1AURKBAURKACCNA2CDK2 | |
| SCHEMBL12404570 | 0.91 | CHEK1 (0.40) | CHEK1AURKBAURKASYKCCNA2 | |
| SCHEMBL12404575 | 0.87 | AURKB (0.42) | CHEK1AURKBAURKACCNA2CDK2 | |
| SCHEMBL12404571 | 0.82 | CHEK1 (0.59) | CHEK1AURKBAURKACCNA2CDK2 | |
| SCHEMBL12404650 | 0.79 | CHEK1 (0.45) | CHEK1AURKBAURKACCNA2CDK2 | |
| SCHEMBL14538390 | 0.79 | CHEK1 (0.45) | CHEK1AURKBAURKACCNA2CDK2 | |
| SCHEMBL13954903 | 0.78 | AURKB (0.56) | CHEK1AURKBAURKAPTK6IRAK4 | |
| SCHEMBL14507498 | 0.78 | CHEK1 (0.60) | CHEK1AURKBAURKACCNA2CDK2 | |
| SCHEMBL14537065 | 0.77 | CHEK1 (0.68) | CHEK1AURKBAURKAPTK6 | |
| SCHEMBL14536769 | 0.76 | AURKB (0.62) | CHEK1AURKBAURKAPTK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140274888-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274888-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | CHEK1 4475/4885AURKB 2005/4885AURKA 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.